trending Market Intelligence /marketintelligence/en/news-insights/trending/QjGCij1vOHxobuj37W3uUg2 content esgSubNav
In This List

AstraZeneca exec to replace GSK's outgoing global pharmaceuticals president

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


AstraZeneca exec to replace GSK's outgoing global pharmaceuticals president

GlaxoSmithKline PLC appointed Luke Miels president of global pharmaceuticals.

Miels, whose start date was not given, is currently AstraZeneca PLC's executive vice president for Europe. Miels will report to GSK CEO Designate Emma Walmsley, who will become permanent CEO in April.

Miels replaces Abbas Hussain, who will leave GlaxoSmithKline later in 2017. Hussain, who joined GSK in 2008, is also a director at HIV-focused ViiV Healthcare.

Before joining AstraZeneca, Miels served Roche as regional vice president Asia-Pacific for the pharmaceuticals division.